Adjusting Effect Estimates for Unmeasured Confounding with Validation Data Using Propensity Score Calibration
Overview
Affiliations
Often, data on important confounders are not available in cohort studies. Sensitivity analyses based on the relation of single, but not multiple, unmeasured confounders with an exposure of interest in a separate validation study have been proposed. In this paper, the authors controlled for measured confounding in the main cohort using propensity scores (PS's) and addressed unmeasured confounding by estimating two additional PS's in a validation study. The "error-prone" PS exclusively used information available in the main cohort. The "gold standard" PS additionally included data on covariates available only in the validation study. Based on these two PS's in the validation study, regression calibration was applied to adjust regression coefficients. This propensity score calibration (PSC) adjusts for unmeasured confounding in cohort studies with validation data under certain, usually untestable, assumptions. The authors used PSC to assess the relation between nonsteroidal antiinflammatory drugs (NSAIDs) and 1-year mortality in a large cohort of elderly persons. "Traditional" adjustment resulted in a hazard ratio for NSAID users of 0.80 (95% confidence interval (CI): 0.77, 0.83) as compared with an unadjusted hazard ratio of 0.68 (95% CI: 0.66, 0.71). Application of PSC resulted in a more plausible hazard ratio of 1.06 (95% CI: 1.00, 1.12). Until the validity and limitations of PSC have been assessed in different settings, the method should be seen as a sensitivity analysis.
Kim D, Park C, Ko D, Lin K, Glynn R Drugs Aging. 2024; 41(7):583-600.
PMID: 38954400 PMC: 11884328. DOI: 10.1007/s40266-024-01121-0.
Challenges in and Opportunities for Electronic Health Record-Based Data Analysis and Interpretation.
Kim M, Rouphael C, McMichael J, Welch N, Dasarathy S Gut Liver. 2023; 18(2):201-208.
PMID: 37905424 PMC: 10938158. DOI: 10.5009/gnl230272.
Griffin B, Schuler M, Cefalu M, Ayer L, Godley M, Greifer N Med Care. 2023; 61(12):836-845.
PMID: 37782463 PMC: 10840831. DOI: 10.1097/MLR.0000000000001922.
Wan F Am J Epidemiol. 2023; 193(2):360-369.
PMID: 37759344 PMC: 11484665. DOI: 10.1093/aje/kwad189.
Strategies to Address Current Challenges in Real-World Evidence Generation in Japan.
Laurent T, Lambrelli D, Wakabayashi R, Hirano T, Kuwatsuru R Drugs Real World Outcomes. 2023; 10(2):167-176.
PMID: 37178273 PMC: 10182751. DOI: 10.1007/s40801-023-00371-5.